iTeos Therapeutics, Inc. $ITOS Stock Holdings Decreased by Russell Investments Group Ltd.

Russell Investments Group Ltd. reduced its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 21.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 45,184 shares of the company’s stock after selling 12,041 shares during the period. Russell Investments Group Ltd. owned about 0.12% of iTeos Therapeutics worth $270,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of iTeos Therapeutics during the fourth quarter worth approximately $42,000. CWM LLC boosted its holdings in shares of iTeos Therapeutics by 428.7% during the first quarter. CWM LLC now owns 8,554 shares of the company’s stock worth $51,000 after purchasing an additional 6,936 shares during the period. Forefront Analytics LLC acquired a new stake in shares of iTeos Therapeutics during the fourth quarter worth approximately $85,000. Graham Capital Management L.P. acquired a new stake in shares of iTeos Therapeutics during the fourth quarter worth approximately $85,000. Finally, Exchange Traded Concepts LLC boosted its holdings in shares of iTeos Therapeutics by 25.1% during the first quarter. Exchange Traded Concepts LLC now owns 17,308 shares of the company’s stock worth $103,000 after purchasing an additional 3,468 shares during the period. 97.16% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director David Hallal sold 38,228 shares of the business’s stock in a transaction on Friday, June 6th. The shares were sold at an average price of $10.24, for a total value of $391,454.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michel Detheux sold 43,883 shares of the business’s stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $10.02, for a total transaction of $439,707.66. Following the completion of the sale, the chief executive officer owned 153,903 shares of the company’s stock, valued at $1,542,108.06. The trade was a 22.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 277,185 shares of company stock valued at $2,805,412 over the last 90 days. 14.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research firms recently commented on ITOS. JPMorgan Chase & Co. cut shares of iTeos Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $15.00 to $8.00 in a report on Tuesday, May 13th. Leerink Partnrs cut shares of iTeos Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, May 14th. HC Wainwright cut shares of iTeos Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 14th. Leerink Partners reiterated a “market perform” rating and issued a $9.00 target price (down from $47.00) on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. Finally, Raymond James Financial set a $12.00 target price on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. One investment analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, iTeos Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $15.50.

iTeos Therapeutics Stock Performance

Shares of iTeos Therapeutics stock opened at $10.15 on Tuesday. The firm has a fifty day simple moving average of $10.14 and a 200-day simple moving average of $8.46. iTeos Therapeutics, Inc. has a 1-year low of $4.80 and a 1-year high of $17.63. The stock has a market capitalization of $448.73 million, a price-to-earnings ratio of -2.17 and a beta of 1.31.

iTeos Therapeutics (NASDAQ:ITOS) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($1.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.39). As a group, research analysts predict that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.